Summary of the primer on tumor immunology and the biological therapy of cancer View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2009-12

AUTHORS

Yufeng Li, Shujuan Liu, Kim Margolin, Patrick Hwu

ABSTRACT

The International Society for Biological Therapy of Cancer (iSBTc) is one of the "premier destinations for interaction and innovation in the cancer biologics community". It provides a primer course each year during the annual meeting to address the most important areas of tumor immunology and immunotherapy. The course has been given by prominent investigators in the area of interest, covering the core principles of cancer immunology and immunotherapy. The target audience for this program includes investigators from academic, regulatory, and biopharmaceutical venues. The program goal is to enable the attendees to learn the current status and the most recent advances in biologic therapies, and to leverage this knowledge towards the improvement of cancer therapy. The 2008 immunologic primer course was held on October 30 at the 23rd Annual meeting of iSBTc in San Diego, CA. Nine internationally renowned investigators gave excellent presentations on different topics. The topics covered in this primer included: (1) cytokines in cancer immunology; (2) anti-angiogenic therapy; (3) end stage: immune killing of tumors; (4) blocking T cell checkpoints; (5) approach to identification and therapeutic exploitation of tumor antigens; (6) T regulatory cells; (7) adoptive T cell therapy; (8) immune monitoring of cancer immunotherapy; and (9) immune adjuvants. We summarized the topics in this primer for public education. The related topic slides and schedule can be accessed online http://www.isbtc.org/meetings/am08/primer08. More... »

PAGES

11

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1479-5876-7-11

DOI

http://dx.doi.org/10.1186/1479-5876-7-11

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1049088361

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19175928


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adjuvants, Immunologic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biological Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytokines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "T-Lymphocytes", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Department of Melanoma Medical Oncology, the University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Yufeng", 
        "id": "sg:person.012176512507.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012176512507.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Melanoma Medical Oncology, the University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liu", 
        "givenName": "Shujuan", 
        "id": "sg:person.07722520737.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07722520737.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Washington", 
          "id": "https://www.grid.ac/institutes/grid.34477.33", 
          "name": [
            "Department of Medicine Division of Oncology, University of Washington, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Margolin", 
        "givenName": "Kim", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Melanoma Medical Oncology, the University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hwu", 
        "givenName": "Patrick", 
        "id": "sg:person.0702415721.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702415721.17"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2009-12", 
    "datePublishedReg": "2009-12-01", 
    "description": "The International Society for Biological Therapy of Cancer (iSBTc) is one of the \"premier destinations for interaction and innovation in the cancer biologics community\". It provides a primer course each year during the annual meeting to address the most important areas of tumor immunology and immunotherapy. The course has been given by prominent investigators in the area of interest, covering the core principles of cancer immunology and immunotherapy. The target audience for this program includes investigators from academic, regulatory, and biopharmaceutical venues. The program goal is to enable the attendees to learn the current status and the most recent advances in biologic therapies, and to leverage this knowledge towards the improvement of cancer therapy. The 2008 immunologic primer course was held on October 30 at the 23rd Annual meeting of iSBTc in San Diego, CA. Nine internationally renowned investigators gave excellent presentations on different topics. The topics covered in this primer included: (1) cytokines in cancer immunology; (2) anti-angiogenic therapy; (3) end stage: immune killing of tumors; (4) blocking T cell checkpoints; (5) approach to identification and therapeutic exploitation of tumor antigens; (6) T regulatory cells; (7) adoptive T cell therapy; (8) immune monitoring of cancer immunotherapy; and (9) immune adjuvants. We summarized the topics in this primer for public education. The related topic slides and schedule can be accessed online http://www.isbtc.org/meetings/am08/primer08.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1479-5876-7-11", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1032886", 
        "issn": [
          "1479-5876"
        ], 
        "name": "Journal of Translational Medicine", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "name": "Summary of the primer on tumor immunology and the biological therapy of cancer", 
    "pagination": "11", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "e9d9690c7e0d6431ba20692a3910d42a4cc351f9106c643dbffd5f867fe5340f"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19175928"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101190741"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1479-5876-7-11"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1049088361"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1479-5876-7-11", 
      "https://app.dimensions.ai/details/publication/pub.1049088361"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T02:03", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8700_00000516.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1479-5876-7-11"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1479-5876-7-11'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1479-5876-7-11'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1479-5876-7-11'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1479-5876-7-11'


 

This table displays all metadata directly associated to this object as RDF triples.

138 TRIPLES      20 PREDICATES      40 URIs      32 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1479-5876-7-11 schema:about N1afdccd2965d4ddbac7745415eb748e9
2 N4f4af1ead74b4d6ab2b6c2d23576d6d0
3 N6d2e68a8a11040f5905c9d5f0e333963
4 N7ebce25a74e446caab8072c687b7a46f
5 N89a8901ed297413298be7ffb34d300ff
6 N907fb2ef79d4419292f46d0051b95706
7 Na941e939d8304030abd348cd54958eba
8 Nb483333ff1744269aebedd670b8ca610
9 Nd21316a482de49c285f09b3801ba1eae
10 Ndc6ca3aa57d7451ea42ce73f8e42722d
11 Nfd4984392d8445289baa5ba7bca0e9fb
12 anzsrc-for:11
13 anzsrc-for:1107
14 schema:author N6f506474f68745f6b81d55d60d5a9a72
15 schema:datePublished 2009-12
16 schema:datePublishedReg 2009-12-01
17 schema:description The International Society for Biological Therapy of Cancer (iSBTc) is one of the "premier destinations for interaction and innovation in the cancer biologics community". It provides a primer course each year during the annual meeting to address the most important areas of tumor immunology and immunotherapy. The course has been given by prominent investigators in the area of interest, covering the core principles of cancer immunology and immunotherapy. The target audience for this program includes investigators from academic, regulatory, and biopharmaceutical venues. The program goal is to enable the attendees to learn the current status and the most recent advances in biologic therapies, and to leverage this knowledge towards the improvement of cancer therapy. The 2008 immunologic primer course was held on October 30 at the 23rd Annual meeting of iSBTc in San Diego, CA. Nine internationally renowned investigators gave excellent presentations on different topics. The topics covered in this primer included: (1) cytokines in cancer immunology; (2) anti-angiogenic therapy; (3) end stage: immune killing of tumors; (4) blocking T cell checkpoints; (5) approach to identification and therapeutic exploitation of tumor antigens; (6) T regulatory cells; (7) adoptive T cell therapy; (8) immune monitoring of cancer immunotherapy; and (9) immune adjuvants. We summarized the topics in this primer for public education. The related topic slides and schedule can be accessed online http://www.isbtc.org/meetings/am08/primer08.
18 schema:genre research_article
19 schema:inLanguage en
20 schema:isAccessibleForFree true
21 schema:isPartOf N507baffdf6014bd2957bb2fc93964cf0
22 Nb5b2760a52f34fc8955bac725e2839dc
23 sg:journal.1032886
24 schema:name Summary of the primer on tumor immunology and the biological therapy of cancer
25 schema:pagination 11
26 schema:productId N402161ea8a134fb2bbd372c6838fd8db
27 N840f9c710fce4202bdac1c962ee1f9ee
28 Na370210e1afc4d0fa8bb0e1b026d4656
29 Nbc3dd009c8f24516864cc6131cc6568b
30 Nf1fc20a8697040a5a973252b37a21a90
31 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049088361
32 https://doi.org/10.1186/1479-5876-7-11
33 schema:sdDatePublished 2019-04-11T02:03
34 schema:sdLicense https://scigraph.springernature.com/explorer/license/
35 schema:sdPublisher N6ee65349c0dd4c0b883ea150a36ef0c4
36 schema:url http://link.springer.com/10.1186%2F1479-5876-7-11
37 sgo:license sg:explorer/license/
38 sgo:sdDataset articles
39 rdf:type schema:ScholarlyArticle
40 N1278ed58704e48eda8b54523c093c505 rdf:first N6b5ad057c6c04a3988d07de741d3f5b6
41 rdf:rest N95674956a85543e0a278903b802fa63a
42 N1afdccd2965d4ddbac7745415eb748e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
43 schema:name Biological Therapy
44 rdf:type schema:DefinedTerm
45 N2eece051f60e4702b51f72b03e1f4102 rdf:first sg:person.07722520737.38
46 rdf:rest N1278ed58704e48eda8b54523c093c505
47 N402161ea8a134fb2bbd372c6838fd8db schema:name doi
48 schema:value 10.1186/1479-5876-7-11
49 rdf:type schema:PropertyValue
50 N4f4af1ead74b4d6ab2b6c2d23576d6d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
51 schema:name Humans
52 rdf:type schema:DefinedTerm
53 N507baffdf6014bd2957bb2fc93964cf0 schema:volumeNumber 7
54 rdf:type schema:PublicationVolume
55 N6b5ad057c6c04a3988d07de741d3f5b6 schema:affiliation https://www.grid.ac/institutes/grid.34477.33
56 schema:familyName Margolin
57 schema:givenName Kim
58 rdf:type schema:Person
59 N6d2e68a8a11040f5905c9d5f0e333963 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Neoplasms
61 rdf:type schema:DefinedTerm
62 N6ee65349c0dd4c0b883ea150a36ef0c4 schema:name Springer Nature - SN SciGraph project
63 rdf:type schema:Organization
64 N6f506474f68745f6b81d55d60d5a9a72 rdf:first sg:person.012176512507.54
65 rdf:rest N2eece051f60e4702b51f72b03e1f4102
66 N7e670241a4b24258ae7466dc82b6bdb7 schema:name Department of Melanoma Medical Oncology, the University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA
67 rdf:type schema:Organization
68 N7ebce25a74e446caab8072c687b7a46f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Immunotherapy
70 rdf:type schema:DefinedTerm
71 N840f9c710fce4202bdac1c962ee1f9ee schema:name pubmed_id
72 schema:value 19175928
73 rdf:type schema:PropertyValue
74 N89a8901ed297413298be7ffb34d300ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Neoplasm Staging
76 rdf:type schema:DefinedTerm
77 N907fb2ef79d4419292f46d0051b95706 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Cell Survival
79 rdf:type schema:DefinedTerm
80 N95674956a85543e0a278903b802fa63a rdf:first sg:person.0702415721.17
81 rdf:rest rdf:nil
82 Na370210e1afc4d0fa8bb0e1b026d4656 schema:name nlm_unique_id
83 schema:value 101190741
84 rdf:type schema:PropertyValue
85 Na941e939d8304030abd348cd54958eba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Cytokines
87 rdf:type schema:DefinedTerm
88 Nb483333ff1744269aebedd670b8ca610 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Angiogenesis Inhibitors
90 rdf:type schema:DefinedTerm
91 Nb5b2760a52f34fc8955bac725e2839dc schema:issueNumber 1
92 rdf:type schema:PublicationIssue
93 Nbc3dd009c8f24516864cc6131cc6568b schema:name readcube_id
94 schema:value e9d9690c7e0d6431ba20692a3910d42a4cc351f9106c643dbffd5f867fe5340f
95 rdf:type schema:PropertyValue
96 Nbeea8fb8477a4ac59b5004dfb159fb89 schema:name Department of Melanoma Medical Oncology, the University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA
97 rdf:type schema:Organization
98 Nd21316a482de49c285f09b3801ba1eae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name T-Lymphocytes
100 rdf:type schema:DefinedTerm
101 Ndc6ca3aa57d7451ea42ce73f8e42722d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Antigens, Neoplasm
103 rdf:type schema:DefinedTerm
104 Nddf2b76af7e74c6eafa2c4344173aef7 schema:name Department of Melanoma Medical Oncology, the University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA
105 rdf:type schema:Organization
106 Nf1fc20a8697040a5a973252b37a21a90 schema:name dimensions_id
107 schema:value pub.1049088361
108 rdf:type schema:PropertyValue
109 Nfd4984392d8445289baa5ba7bca0e9fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Adjuvants, Immunologic
111 rdf:type schema:DefinedTerm
112 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
113 schema:name Medical and Health Sciences
114 rdf:type schema:DefinedTerm
115 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
116 schema:name Immunology
117 rdf:type schema:DefinedTerm
118 sg:journal.1032886 schema:issn 1479-5876
119 schema:name Journal of Translational Medicine
120 rdf:type schema:Periodical
121 sg:person.012176512507.54 schema:affiliation Nddf2b76af7e74c6eafa2c4344173aef7
122 schema:familyName Li
123 schema:givenName Yufeng
124 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012176512507.54
125 rdf:type schema:Person
126 sg:person.0702415721.17 schema:affiliation N7e670241a4b24258ae7466dc82b6bdb7
127 schema:familyName Hwu
128 schema:givenName Patrick
129 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702415721.17
130 rdf:type schema:Person
131 sg:person.07722520737.38 schema:affiliation Nbeea8fb8477a4ac59b5004dfb159fb89
132 schema:familyName Liu
133 schema:givenName Shujuan
134 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07722520737.38
135 rdf:type schema:Person
136 https://www.grid.ac/institutes/grid.34477.33 schema:alternateName University of Washington
137 schema:name Department of Medicine Division of Oncology, University of Washington, Seattle, WA, USA
138 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...